You are here

  • Home
  • Online First
  • Compatibility of pentoxifylline injection with syringe and inline filters

Article Text

Article menu
Download PDFPDF
Letter
Compatibility of pentoxifylline injection with syringe and inline filters
  1. D Thisuri N De Silva1,
  2. Tobias Strunk2,3,4,
  3. Michael Petrovski5,
  4. Nabeelah Mukadam6,
  5. Kevin T Batty1
  1. 1Curtin Medical School, Curtin University, Bentley, Western Australia, Australia
  2. 2Neonatal Directorate, King Edward Memorial Hospital, Child and Adolescent Health Service, Subiaco, Western Australia, Australia
  3. 3Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute Australia, Nedlands, Western Australia, Australia
  4. 4Medical School, The University of Western Australia, Crawley, Western Australia, Australia
  5. 5Pharmacy Department, Sir Charles Gairdner Hospital, North Metropolitan Health Service, Nedlands, Western Australia, Australia
  6. 6Pharmacy Department, King Edward Memorial Hospital, Women and Newborn Health Service, Subiaco, Western Australia, Australia
  1. Correspondence to Dr Kevin T Batty; kevin.batty{at}curtin.edu.au

https://doi.org/10.1136/archdischild-2024-327377

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Pentoxifylline (PTX) is used as an adjunct to the antimicrobial treatment of neonatal sepsis and is commonly administered as a 6-hour or 12-hour intravenous infusion.1 In the neonatal intensive care unit (NICU) setting, commercially available PTX injection is normally diluted with 0.9% w/v sodium chloride injection to a concentration of 5 mg/mL for intravenous delivery via a syringe pump. In clinical settings, some injectable solutions may be filtered using syringes or inline filters to ensure there are no glass fragments, precipitated drugs or other particulate matter in the final product.

    Recent studies have shown that PTX is compatible with a wide range of intravenous medicines used in NICU settings2–4; however, the compatibility of PTX with inline intravenous filters or syringe filters used in aseptic compounding facilities has not previously been reported.

    In the present …

    View Full Text

    Footnotes

    • Contributors All authors contributed to the study design, interpretation of data and manuscript preparation. DTNDS and KTB had principal responsibility for acquiring the data, initial analysis and first draft of the manuscript. KTB is the guarantor and accepts full responsibility for the conduct of the study.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Author note The present study complements an ongoing clinical trial, 'PROTECT (Pentoxifylline to Protect the Preterm Brain)'; registration ID: ACTRN12616000405415.